DE69938255D1 - Verfahren und zusammensetzung zur konservierung von adenoviren - Google Patents
Verfahren und zusammensetzung zur konservierung von adenovirenInfo
- Publication number
- DE69938255D1 DE69938255D1 DE69938255T DE69938255T DE69938255D1 DE 69938255 D1 DE69938255 D1 DE 69938255D1 DE 69938255 T DE69938255 T DE 69938255T DE 69938255 T DE69938255 T DE 69938255T DE 69938255 D1 DE69938255 D1 DE 69938255D1
- Authority
- DE
- Germany
- Prior art keywords
- composition
- preserving
- adenovires
- adenoviral
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US208666 | 1998-12-10 | ||
| US09/208,666 US6225289B1 (en) | 1998-12-10 | 1998-12-10 | Methods and compositions for preserving adenoviral vectors |
| PCT/US1999/029271 WO2000034444A2 (en) | 1998-12-10 | 1999-12-10 | Method and composition for preserving viruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69938255D1 true DE69938255D1 (de) | 2008-04-10 |
| DE69938255T2 DE69938255T2 (de) | 2009-02-12 |
Family
ID=22775503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69938255T Expired - Fee Related DE69938255T2 (de) | 1998-12-10 | 1999-12-10 | Verfahren und zusammensetzung zur konservierung von adenoviren |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6225289B1 (de) |
| EP (1) | EP1137758B1 (de) |
| JP (1) | JP2002531119A (de) |
| AT (1) | ATE387492T1 (de) |
| AU (1) | AU771112C (de) |
| CA (1) | CA2351890A1 (de) |
| DE (1) | DE69938255T2 (de) |
| DK (1) | DK1137758T3 (de) |
| ES (1) | ES2299275T3 (de) |
| WO (1) | WO2000034444A2 (de) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| CN1244215B (zh) | 1996-11-20 | 2010-11-03 | 荷兰克鲁塞尔公司 | 改进的腺病毒载体生产和纯化方法 |
| US7569342B2 (en) * | 1997-12-10 | 2009-08-04 | Sierra Molecular Corp. | Removal of molecular assay interferences |
| US20080064108A1 (en) * | 1997-12-10 | 2008-03-13 | Tony Baker | Urine Preservation System |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| AU778894B2 (en) * | 1999-04-09 | 2004-12-23 | Centelion S.A.S. | Composition for the preservation of infectious recombinant adenoviruses |
| US7456009B2 (en) * | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| EP2420247A1 (de) * | 2000-03-07 | 2012-02-22 | Merck Sharp & Dohme Corp. | Adenovirus-Formulierungen |
| WO2001085928A1 (fr) * | 2000-05-10 | 2001-11-15 | Mitsubishi Pharma Corporation | Procede de preparation de vecteur de virus |
| CA2349098C (en) * | 2000-05-30 | 2011-03-01 | Integrated Biomedical Technology, Inc. | Assay for aldehyde content |
| US7125549B2 (en) * | 2000-05-31 | 2006-10-24 | Human Gene Therapy Research Institute | Methods and compositions for efficient gene transfer using transcomplementary vectors |
| ES2180416B1 (es) | 2001-03-12 | 2004-06-01 | BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. | Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen. |
| DK1418942T3 (da) * | 2001-12-10 | 2005-11-28 | Bavarian Nordic As | Poxvirus-holdige sammensætninger og fremgangsmåde til fremstilling deraf |
| CA2469491A1 (en) * | 2001-12-12 | 2003-06-19 | Kerrie Setiawan | Composition for viral preservation |
| US20030153065A1 (en) * | 2002-01-14 | 2003-08-14 | Genvec, Inc. | Composition and method for maintaining non-enveloped viral vectors |
| GB0209680D0 (en) * | 2002-04-27 | 2002-06-05 | Univ Strathclyde | Immobilisation and stabilisation of bacteriophage |
| AU2003291526A1 (en) * | 2002-11-15 | 2004-06-15 | Genvec, Inc | Coronary artery disease treatment |
| ES2391975T3 (es) * | 2003-07-25 | 2012-12-03 | Genvec, Inc. | Vacunas a base de vector adenovírico |
| WO2005051432A1 (en) * | 2003-11-14 | 2005-06-09 | Genvec, Inc. | Therapeutic regimen for treating cancer |
| WO2005066333A1 (en) * | 2003-12-30 | 2005-07-21 | Aventis Pasteur, Inc. | Stabilizing compositions for recombinant viruses |
| DK1732588T3 (da) | 2004-04-05 | 2009-10-12 | Univ California | Modulation af NKG2D |
| CN1972958B (zh) | 2004-04-12 | 2013-01-23 | 美国政府卫生与公共服务部 | 应用腺病毒载体诱导免疫应答的方法 |
| DK1757312T3 (da) * | 2004-06-14 | 2011-04-11 | Ishihara Sangyo Kaisha | Frysetørret sammensætning af inaktiveret viruskappe med membranfusionsaktivitet |
| CA2573702C (en) | 2004-07-16 | 2013-10-15 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Vaccine constructs and combination of vaccines designed to improve the breadth of the immune response to diverse strains and clades of hiv |
| WO2006039045A2 (en) * | 2004-09-01 | 2006-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
| AU2005305347A1 (en) | 2004-11-03 | 2006-05-18 | Introgen Therapeutics Inc. | Method of producing and purifying of adenoviral vectors |
| ES2732623T3 (es) | 2005-01-06 | 2019-11-25 | Innate Pharma Sa | Tratamientos y métodos de combinación anti-KIR |
| EP1929021A2 (de) * | 2005-08-31 | 2008-06-11 | Genvec, Inc. | Malariaimpfstoffe auf adenovirusvektorbasis |
| BRPI0618441B8 (pt) * | 2005-11-10 | 2021-07-27 | Genvec Inc | vetor adenoviral |
| WO2007056847A1 (en) * | 2005-11-21 | 2007-05-24 | Sanofi Pasteur Limited | Stabilizing formulations for recombinant viruses |
| DK2010014T3 (da) * | 2006-03-07 | 2010-02-08 | Dritte Patentportfolio Beteili | Solubilisater af konserveringsmidler og fremgangsmåde til fremstilling heraf |
| EP2101797B1 (de) * | 2006-12-01 | 2015-08-26 | HepC Terápia Kereskedelmi és Szolgáltató Zártkörüen Müködö Részvénytársaság | Zusammensetzungen und methoden zur behandlung viraler hepatitis |
| US20100278870A1 (en) * | 2007-01-09 | 2010-11-04 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Adenoviral vector-based malaria vaccines |
| PL2612868T3 (pl) | 2007-11-01 | 2018-12-31 | Astellas Pharma Inc. | Immunosupresyjne polipeptydy i kwasy nukleinowe |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| US9605844B2 (en) * | 2009-09-01 | 2017-03-28 | Cree, Inc. | Lighting device with heat dissipation elements |
| CA2775273A1 (en) * | 2009-10-22 | 2011-04-28 | Biotools Biotechnological & Medical Laboratories, S.A. | Composition, method and kit for detecting bacteria by means of sequencing |
| WO2011057254A2 (en) | 2009-11-09 | 2011-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Simian adenoviral vector-based vaccines |
| US9682133B2 (en) | 2010-03-17 | 2017-06-20 | Cornell University | Disrupted adenovirus-based vaccine against drugs of abuse |
| TWI688395B (zh) | 2010-03-23 | 2020-03-21 | 英翠克頌公司 | 條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途 |
| WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
| CN103118702A (zh) | 2010-09-20 | 2013-05-22 | 克鲁塞尔荷兰公司 | 活动性结核病的治疗性接种 |
| MX354752B (es) | 2010-09-27 | 2018-03-20 | Janssen Vaccines & Prevention Bv | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. |
| SG190419A1 (en) | 2010-12-02 | 2013-06-28 | Oncolytics Biotech Inc | Lyophilized viral formulations |
| AU2011336413B2 (en) | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Liquid viral formulations |
| WO2012083297A2 (en) | 2010-12-17 | 2012-06-21 | Genvec, Inc. | Adenoviral vectors with modified hexon regions |
| EP2654786B1 (de) | 2010-12-20 | 2019-02-20 | GenVec, Inc. | Auf adenovirusvektor basierender impfstoff gegen denguefieber |
| WO2012122025A2 (en) | 2011-03-04 | 2012-09-13 | Intrexon Corporation | Vectors conditionally expressing protein |
| EP2714741B1 (de) | 2011-05-25 | 2019-10-30 | Innate Pharma, S.A. | Anti-kir-antikörper zur behandlung entzündlicher erkrankungen |
| EP2764012B1 (de) | 2011-10-05 | 2022-02-23 | GenVec, Inc. | Adenovirusvektoren und verwendungsverfahren dafür |
| US9580476B2 (en) | 2011-10-05 | 2017-02-28 | Genvec, Inc. | Adenoviral vector-based respiratory syncytial virus (RSV) vaccine |
| CN107574154A (zh) | 2011-10-05 | 2018-01-12 | 金维克有限公司 | 猴(大猩猩)腺病毒或腺病毒载体及其使用方法 |
| BR112014008249B1 (pt) | 2011-10-05 | 2022-03-15 | Genvec Inc | Adenovírus ou vetor adenoviral e composição com os mesmos |
| WO2013116591A1 (en) | 2012-02-02 | 2013-08-08 | Genvec, Inc. | Adenoviral vector-based malaria vaccine |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| WO2013135615A1 (en) | 2012-03-12 | 2013-09-19 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| MY169331A (en) | 2012-03-22 | 2019-03-21 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
| US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
| US9676824B2 (en) | 2012-05-29 | 2017-06-13 | Genvec, Inc. | Herpes simplex virus vaccine |
| EP2855669B1 (de) | 2012-05-29 | 2018-10-10 | GenVec, Inc. | Modifizierte serotyp-28-adenovirusvektoren |
| WO2014093270A1 (en) | 2012-12-10 | 2014-06-19 | Virginia Commonwealth University | Tropism modified cancer terminator virus (ad.5/3 ctv;ad.5/3-ctv-m7) |
| KR102236497B1 (ko) | 2013-04-25 | 2021-04-06 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드 |
| US10294279B2 (en) | 2013-06-17 | 2019-05-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| AP2016009154A0 (en) | 2013-09-19 | 2016-04-30 | Crucell Holland Bv | Improved adenovirus formulations |
| WO2015040234A1 (en) * | 2013-09-23 | 2015-03-26 | Crucell Holland B.V. | Adenovirus formulations |
| TWI710635B (zh) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
| WO2016154055A1 (en) * | 2015-03-20 | 2016-09-29 | Bluebird Bio, Inc. | Vector formulations |
| AU2016249798B2 (en) | 2015-04-14 | 2022-05-26 | Janssen Vaccines And Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
| PL3319633T3 (pl) | 2015-07-07 | 2021-04-19 | Janssen Vaccines & Prevention B.V. | Szczepionka przeciwko rsv |
| EP3319634B1 (de) | 2015-07-07 | 2019-08-21 | Janssen Vaccines & Prevention B.V. | Stabilisierte lösliche präfusionierte rsv-f-polypeptide |
| JP7233928B2 (ja) | 2016-04-05 | 2023-03-07 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｒｓｖに対するワクチン |
| SI3439672T1 (sl) | 2016-04-05 | 2021-02-26 | Janssen Vaccines & Prevention B.V. | Stabiliziran topen pre-fuzijski F protein RSV za uporabo v profilaksi okužbe z RSV |
| CN109154000B (zh) | 2016-05-12 | 2022-07-05 | 扬森疫苗与预防公司 | 有效和平衡的双向启动子 |
| EA039124B1 (ru) | 2016-05-30 | 2021-12-08 | Янссен Вэксинс Энд Превеншн Б.В. | Стабилизированные f-белки rsv до слияния |
| EP3472327B1 (de) | 2016-06-20 | 2020-08-19 | Janssen Vaccines & Prevention B.V. | Potenter und ausbalancierter bidirektionaler promotor |
| EP3484506A1 (de) | 2016-07-14 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Hpv-impfstoffe |
| US11155832B2 (en) | 2016-09-30 | 2021-10-26 | Genvec, Inc. | Adenovectors for delivery of therapeutic genetic material into T cells |
| BR112019011394A2 (pt) | 2016-12-05 | 2019-12-10 | Nuritas Ltd | composições compreendendo peptídeo wkdeagkplvk |
| EP3329930A1 (de) | 2016-12-05 | 2018-06-06 | Nuritas Limited | Pharmazeutische zusammensetzungen |
| BR112019015671A2 (pt) | 2017-02-09 | 2020-04-14 | Janssen Vaccines & Prevention Bv | promotor potente e curto para expressão de genes heterológicos |
| CA3061278A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| AU2018333566A1 (en) | 2017-09-15 | 2020-02-27 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against RSV |
| CA3092935A1 (en) | 2018-03-06 | 2019-09-12 | Precigen, Inc. | Hepatitis b vaccines and uses of the same |
| WO2020172509A1 (en) | 2019-02-21 | 2020-08-27 | Unleash Immuno Oncolytics, Inc. | Oncolytic adenoviral vector and methods of use |
| US20230075527A1 (en) | 2020-01-31 | 2023-03-09 | Janssen Pharmaceuticals, Inc | Compositions and Methods for Preventing and Treating Coronavirus Infection - Sars-Cov-2 Vaccines |
| AU2021357520A1 (en) | 2020-03-05 | 2022-09-29 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
| IL303113A (en) | 2020-11-25 | 2023-07-01 | Precigen Inc | Human papillomavirus vaccines and their uses for human papillomavirus-related diseases |
| AU2022221983A1 (en) | 2021-02-19 | 2023-08-17 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE299213C (de) | ||||
| DE1617457A1 (de) * | 1966-12-16 | 1972-04-20 | Erba Carlo Spa | Verfahren zur Stabilisierung von Zubereitungen interferierender Virusprodukte |
| US3915794A (en) | 1973-02-09 | 1975-10-28 | Rit Rech Ind Therapeut | Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them |
| US4337242A (en) | 1980-02-05 | 1982-06-29 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
| US4338335A (en) | 1980-02-05 | 1982-07-06 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
| WO1987000196A1 (en) | 1985-07-09 | 1987-01-15 | Quadrant Bioresources Limited | Protection of proteins and the like |
| US4678812A (en) | 1986-05-30 | 1987-07-07 | E. I. Du Pont De Nemours And Company | Trehalose as stabilizer and tableting excipient |
| US4762857A (en) | 1986-05-30 | 1988-08-09 | E. I. Du Pont De Nemours And Company | Trehalose as stabilizer and tableting excipient |
| GB8801338D0 (en) | 1988-01-21 | 1988-02-17 | Quadrant Bioresources Ltd | Preservation of viruses |
| GB8802174D0 (en) | 1988-02-01 | 1988-03-02 | Quadrant Bioresources Ltd | Method of drying macromolecules |
| GB8917470D0 (en) | 1989-07-31 | 1989-09-13 | Quadrant Bioresources Ltd | Composition and method |
| GB9010742D0 (en) | 1990-05-14 | 1990-07-04 | Quadrant Bioresources Ltd | Stabilization of biological macromolecular substances |
| CA2051092C (en) | 1990-09-12 | 2002-07-23 | Stephen A. Livesey | Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions |
| DE69227805T2 (de) | 1991-07-05 | 1999-04-29 | Bayer Ag | Verwendung von Tri-n-Butylphosphat bei niedrigem pH in Lösungen von biologisch aktiven Proteinen für eine verbesserte viruzide Wirkung |
| EP0624190A4 (de) | 1992-01-21 | 1995-04-19 | Cryopharm Corp | Methode zum einfrieren von zellen und zellähnlichen materialien. |
| CA2158935A1 (en) | 1993-10-12 | 1995-04-20 | Chiron Viagene, Inc. | Methods for preserving recombinant viruses |
| ATE336587T1 (de) | 1994-06-10 | 2006-09-15 | Genvec Inc | Adenoviren-vektor systeme und zelllinien |
| US5616487A (en) * | 1994-09-15 | 1997-04-01 | Aastrom Biosciences, Inc. | Stabilized retrovirus compositions |
| AU4954496A (en) | 1995-03-17 | 1996-10-08 | Hisamitsu Pharmaceutical Co., Inc. | Gene transfer preparation |
| DE69636889T2 (de) * | 1995-11-30 | 2007-12-06 | Nof Corp. | Öladjuvierter Impfstoff und Verfahren zu seiner Herstellung |
| FR2751343B1 (fr) * | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| US7732129B1 (en) * | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
-
1998
- 1998-12-10 US US09/208,666 patent/US6225289B1/en not_active Expired - Lifetime
-
1999
- 1999-12-10 DE DE69938255T patent/DE69938255T2/de not_active Expired - Fee Related
- 1999-12-10 AT AT99966096T patent/ATE387492T1/de not_active IP Right Cessation
- 1999-12-10 ES ES99966096T patent/ES2299275T3/es not_active Expired - Lifetime
- 1999-12-10 CA CA002351890A patent/CA2351890A1/en not_active Abandoned
- 1999-12-10 WO PCT/US1999/029271 patent/WO2000034444A2/en active IP Right Grant
- 1999-12-10 EP EP99966096A patent/EP1137758B1/de not_active Expired - Lifetime
- 1999-12-10 AU AU21724/00A patent/AU771112C/en not_active Ceased
- 1999-12-10 JP JP2000586878A patent/JP2002531119A/ja active Pending
- 1999-12-10 DK DK99966096T patent/DK1137758T3/da active
-
2001
- 2001-05-31 US US09/870,920 patent/US6514943B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000034444A3 (en) | 2000-10-26 |
| US20020019041A1 (en) | 2002-02-14 |
| AU2172400A (en) | 2000-06-26 |
| AU771112B2 (en) | 2004-03-11 |
| DK1137758T3 (da) | 2008-06-09 |
| ATE387492T1 (de) | 2008-03-15 |
| EP1137758A2 (de) | 2001-10-04 |
| US6225289B1 (en) | 2001-05-01 |
| WO2000034444A2 (en) | 2000-06-15 |
| DE69938255T2 (de) | 2009-02-12 |
| ES2299275T3 (es) | 2008-05-16 |
| US6514943B2 (en) | 2003-02-04 |
| AU771112C (en) | 2004-11-11 |
| CA2351890A1 (en) | 2000-06-15 |
| JP2002531119A (ja) | 2002-09-24 |
| EP1137758B1 (de) | 2008-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69938255D1 (de) | Verfahren und zusammensetzung zur konservierung von adenoviren | |
| GB8613481D0 (en) | Translation of mrna | |
| BRPI0415409A (pt) | uso de efetuadores de ciclases de glutaminila e glutamato | |
| ID26033A (id) | Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan | |
| AR020054A1 (es) | COMPOSICIoN QUE COMPRENDE UN ADENOVIRUS | |
| MY133996A (en) | Compounds for the treatment of ischemia | |
| ATE421337T1 (de) | Adenovirus-formulierungen zur gentherapie | |
| NO973685L (no) | Multi-tumor avvikende vekstgener | |
| ATE253063T1 (de) | 5-ht1f-agonisten | |
| NO20005161L (no) | N,N-disubstituerte amider som inhiberer bindingen av integriner til deres reseptorer | |
| AR024138A1 (es) | Inhibidores de la proliferacion celular | |
| DK0633763T3 (da) | Kosmetiske eller farmaceutiske sammensætninger indeholdende deacylerede glycerophospholipider til topisk brug | |
| ES2079068T3 (es) | 2-amino-6-fenil-4h-piran-4-onas antiateroscleroticas y antitromboticas. | |
| BR9407693A (pt) | Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto | |
| IL144199A0 (en) | Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions | |
| BR9909237A (pt) | Inibidores de farnesil-proteìna transferase | |
| TR200001724T2 (tr) | 5-HT1F Agonistleri | |
| ATE267018T1 (de) | Verwendung von peptidverbindungen zur behandlung von sle | |
| BR9712851A (pt) | Composições farmacêuticas compreendendo derivados de salquilisotiourÈnio | |
| ATE224195T1 (de) | Glucocorticoide zur behandlung von glomerulonephitis | |
| AP2002002493A0 (en) | Sodium-hydrogen exchanger type 1 inhibitor crystals. | |
| BR9807920A (pt) | Processos para tratamento de uma demência em um sujeito e para prevenção de uma demência | |
| ATE292970T1 (de) | Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden | |
| WO2003049691A3 (en) | Antisense modulation of pctaire protein kinase 1 expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |